EpilepsyGTx

To add a bio or update company history, please click update information.

News from EpilepsyGTx

$EpilepsyGTx secures £25m Series A from investors to advance gene therapies for refractory epilepsy$ $EpilepsyGTx secures £25m Series A from investors to advance gene therapies for refractory epilepsy$

EpilepsyGTx

10 Dec 2025

EpilepsyGTx secures £25m Series A from investors to advance gene therapies for refractory epilepsy

EpilepsyGTx develops gene therapies for severe epilepsy, aiming to stop seizures with a single targeted treatment rather than long-term medication.

EpilepsyGTx

Life Sciences
Cambridge, United Kingdom
£25m
epilepsygtx.com
Update Information

More venture news

Semarion
31 Mar 2026
Semarion secures £2.9m in funding led by Parkwalk to accelerate cell-based drug discovery
EquityLife Sciences
Sequential Bio
17 Mar 2026
Sequential secures £2.6m in funding led by Sparkfood and Corundum Systems Biology for non-invasive testing of skin health ingredients
EquityLife Sciences
Mestag Therapeutics
16 Mar 2026
Mestag Therapeutics secures £30m to advance fibroblast immunology cancer therapies
EquityLife Sciences

EpilepsyGTx

News from EpilepsyGTx

EpilepsyGTx secures £25m Series A from investors to advance gene therapies for refractory epilepsy

More venture news

Semarion secures £2.9m in funding led by Parkwalk to accelerate cell-based drug discovery

Sequential secures £2.6m in funding led by Sparkfood and Corundum Systems Biology for non-invasive testing of skin health ingredients

Mestag Therapeutics secures £30m to advance fibroblast immunology cancer therapies